Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Determinants of Bacille Calmette-Guérin scarification in Danish children

Research output: Contribution to journalJournal articlepeer-review

  1. Outcome of 5-year follow-up in men with negative findings on initial biparametric MRI

    Research output: Contribution to journalJournal articlepeer-review

  2. Possible mechanisms involved in improved beta cell function in pregnant women with type 1 diabetes

    Research output: Contribution to journalJournal articlepeer-review

  3. Using simulation to help healthcare professionals relaying patient information during telephone conversations

    Research output: Contribution to journalJournal articlepeer-review

  4. Okay, let's talk - short debriefings in the operating room

    Research output: Contribution to journalJournal articlepeer-review

View graph of relations

Background: Studies in low-income countries have shown that among Bacille Calmette-Guérin (BCG) vaccinated children, those who develop a BCG-scar have significantly better survival than those who do not develop a scar. In a Danish multicenter randomized clinical trial we assessed determinants for developing a BCG-scar and for BCG scar size following neonatal BCG vaccination.

Methods: At three Danish hospitals, newborns were randomized 1:1 to BCG vaccination or no BCG vaccination. The infants were invited for a clinical examination at the ages of 3 and 13 months. At 13 months, the scar site was inspected and scar size measured. We investigated three groups of determinants; external, parental, and individual-level determinants on relative scar prevalence and differences in median scar sizes.

Results: Among 2118 BCG vaccinated infants, 2039 (96 %) were examined at 13 months; 1857 of these (91 %) had developed a BCG-scar. Compared with Copenhagen University Hospital, Hvidovre (85 %), Copenhagen University Hospital, Rigshospitalet had a scar prevalence of 95 % (adjusted Prevalence ratio (aPR) = 1.24 [CI 95 %: 1.18 to 1.30]); it was 93 % at Kolding Hospital (aPR 1.27 [CI 95 %: 1.19 to 1.35]). Increasing vaccine experience was positively associated with developing a scar and with scar size.

Conclusion: Across multiple potential determinants of BCG scaring and size, logistical factors dominated. The results support that injection technique is an important determinant of developing a scar. Given the strong link between having a BCG scar and subsequent health, improved BCG vaccination technique could play a major role for child health.

Original languageEnglish
Article numbere05757
Issue number1
Pages (from-to)1-10
Number of pages10
Publication statusPublished - 4 Jan 2021

Bibliographical note

Publisher Copyright:
© 2020 The Authors

Copyright 2020 Elsevier B.V., All rights reserved.

    Research areas

  • BCG scar, BCG vaccine, Heterologous immunity, Non-specific effects

ID: 61845496